Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Inclusion Criteria: * Adult subjects who are in complete remission at Day +100 after a bone marrow transplant for Hodgkins Lymphoma * Normal AST or ALT, serum creatinine and 12-lead electrocardiogram within the previous 6 months * Females of childbearing potential must have negative beta-HCG (urine or plasma) within the last month and agree to effective contraception during the course of the study * Willingness and ability to give informed consent * Willingness and ability to take pills twice a day for 28 days Exclusion Criteria: * Known HIV positive * Screening ALT or AST greater than 3X upper limit of normal * Baseline QTc greater than 500 msec * Current treatment with immunosuppressive agent (systemic glucocorticoid, cyclosporine, mycophenolate, azathioprine, sirolimus, Rituximab, infliximab, adalimumab) * Current treatment with any of the following: cisapride, ergot derivatives, amiodarone, quinidine, terfenadine, astemizole, rifampin/rifabutin, carbamazepine, phenobarbital, sildenafil, St. John's wort, azithromycin, carbamazepine, HIV anti-virals, methadone, pimozide, phenytoin, sedative hypnotics (midazolam, triazolam), HMG-CoA reductase inhibitors (lovastatin, simvastatin, atorvastatin) * Active malignancy requiring chemotherapy or radiation * Baseline creatinine of \> 2.0 * Active infection requiring systemic anti-infective agent (excluding prophylactic antibiotics) * Hypersensitivity to processed bovine gelatin, chicken protein, neomycin, amphotericin B or chlortetracycline * Subject must not be on medications that interact with the metabolism of protease inhibitors